newsfilter
← Latest News
Business Wire·

Vistagen Appoints Paul Edick to its Board of Directors

Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with